GSK announces the acquisition of US biotech company RAPT Therapeutics for $2.2 billion.[1][2] The company will pay $58 per share, a 65% premium to the previous day's closing RAPT stock price.[1][2] The acquisition will strengthen GSK's offering in respiratory diseases, immunology and inflammation.[1] The main target is the experimental food allergy drug ozureprubart, for which GSK is acquiring global rights except for mainland China, Macau, Taiwan and Hong Kong.[1][2] Ozureprubart allows dosing once every 12 weeks instead of the current standard of 2–4 weeks.[2] The transaction includes an upfront payment of $1.9 billion.[1] The acquisition follows the previous purchase of Aiolos Bio in 2024 and fits into GSK's strategy focused on immunology and oncology.[2] GSK retains a 78.3% majority stake in ViiV Healthcare for HIV therapies.[1]